WALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the second quarter ended June 30, 2016. Detailed in this press release are the Company's performance highlights for the period, followed by updated financial guidance for the year 2016 and access information for today's webcast and conference call.
Tony J. Hunt, President and Chief Executive Officer said, “We continue to be encouraged by the strength in demand for our bioprocessing products and the positive trends in our industry. We achieved record revenue of $29.2 million in the second quarter of 2016, an increase of 36% from the same period in 2015, driven by strong demand for OPUS® purification columns, XCell™ ATF systems and growth factors. It was also an important quarter in terms of executing on our long-term growth strategy. In April, we acquired Atoll GmBH (“Atoll”), and in May we completed a $115 million convertible debt financing to support ongoing acquisition initiatives as well as internal investments to expand our global infrastructure.”
Tony J. Hunt, President and Chief Executive Officer said, “We continue to be encouraged by the strength in demand for our bioprocessing products and the positive trends in our industry. We achieved record revenue of $29.2 million in the second quarter of 2016, an increase of 36% from the same period in 2015, driven by strong demand for OPUS® purification columns, XCell™ ATF systems and growth factors. It was also an important quarter in terms of executing on our long-term growth strategy. In April, we acquired Atoll GmBH (“Atoll”), and in May we completed a $115 million convertible debt financing to support ongoing acquisition initiatives as well as internal investments to expand our global infrastructure.”
